Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment (EVACUATE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04434807 |
Recruitment Status :
Recruiting
First Posted : June 17, 2020
Last Update Posted : October 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Intra Cerebral Hemorrhage Stroke | Procedure: Minimally invasive hematoma evacuation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 240 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Patients will receive either minimally invasive hematoma evacuation or standard medical therapy |
Masking: | Single (Outcomes Assessor) |
Masking Description: | The primary outcome of Modified Rankin scale (mRS) and secondary outcomes including National Institutes of Health Stroke Scale (NIHSS) are assessed by a blinded clinician. |
Primary Purpose: | Treatment |
Official Title: | Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment (EVACUATE) |
Actual Study Start Date : | November 15, 2020 |
Estimated Primary Completion Date : | December 2025 |
Estimated Study Completion Date : | December 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Minimally invasive hematoma evacuation
Patients randomized to minimally invasive hematoma evacuation will have neurosurgery followed by standard medical therapy in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition.
|
Procedure: Minimally invasive hematoma evacuation
Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences) |
No Intervention: Standard care (medical therapy)
Patients randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage in a stroke care unit or intensive care unit, as appropriate to the patients clinical condition, with no planned surgical intervention.
|
- Dichotomized Modified Rankin Scale Score 0-3 vs. 4-6 at 6 months post-onset (Adjusted) [ Time Frame: 6 months post-stroke ]Modified Rankin Scale (mRS) 0-3 at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume.
- Dichotomized Modified Rankin Scale Score 0-2 or no change from baseline vs. 3-6 at 6 months post-onset (adjusted) [ Time Frame: 6 months post-stroke ]Modified Rankin Scale (mRS) 0-2 or no change from baseline at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume
- Ordinal analysis of Modified Rankin Scale Score at 6 months post-onset (adjusted) [ Time Frame: 6 months post-stroke ]Ordinal analysis of Modified Rankin Scale Score (merging mRS 5-6) at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume
- Utility-weighted analysis of Modified Rankin Scale Score at 6 months post-onset (adjusted) [ Time Frame: 6 months post-stroke ]Utility-weighted analysis of Modified Rankin Scale Score at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume
- Reduction in hematoma volume at 24 hours >70% or <15mL residual volume (adjusted) [ Time Frame: 24 hours post-randomization ]Reduction in hematoma volume at 24 hours >70% or <15mL residual volume, adjusted for immediate pre-treatment ICH volume
- Proportion of patients with early neurological improvement at 7 days (adjusted) [ Time Frame: 7 days post-stroke ]Proportion of patients with ≥8 point reduction in National Institutes of Health Stroke Scale (NIHSS) score or reaching 0-1 at 7 days (or at discharge if earlier) adjusted for baseline NIHSS and age
- Safety: Death due to any cause at 6 months (adjusted) [ Time Frame: 6 months post-stroke ]Death due to any cause at 6 months, adjusted for age, baseline GCS, immediate pre-treatment ICH volume and immediate pre-treatment IVH volume.
- Safety: Hematoma growth or reaccumulation at 24 hours [ Time Frame: 24 hours post-randomization ]Hematoma growth or reaccumulation defined as >33% or >6mL increased volume between baseline and 24 hour scans (or in the intervention arm a hematoma volume on the follow-up scan exceeding the immediate pre-treatment volume), adjusted for the pre-treatment ICH volume.
- Intermediate outcome measure (primary outcome measure for Phase 2b component): Reduction in hematoma volume at 24 hours >70% or <15mL residual volume (adjusted) [ Time Frame: 24 hours post-randomization ]Intermediate outcome measure (primary outcome measure for the Phase 2b component to be analysed for the first 52 patients): Reduction in hematoma volume at 24 hours >70% or <15mL residual volume, adjusted for immediate pre-treatment ICH volume
- Patient Reported Outcomes Measurement Information System (PROMIS10) [ Time Frame: 6 and 12 months post-stroke ]
- Modified Rankin Scale (mRS) 0-2, 0-3, ordinal and utility-weighted analysis at 12 months [ Time Frame: 12 months post-stroke ]
- Assessment of Quality of Life (EQ5D) at 12 months [ Time Frame: 12 months post-stroke ]Assessment of Quality of Life (EQ5D) at 12 months (mapped to mRS at baseline)
- Length of stay in intensive care unit, acute hospital, acute hospital and rehabilitation [ Time Frame: 6 months post-stroke ]
- Home time - time spent at home in the first 6 months [ Time Frame: 6 months post-stroke ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with an acute supratentorial intracerebral hemorrhage (ICH) ≥20mL in volume
- Age ≥18 years
- Surgery can commence within 8 hours of symptom onset (the time the patient was last known to be well) or, in patients with wake-up onset, within 8 hours of the time the patient awoke with symptoms. Patients presenting with small ICH (volume <20mL) with clinical deterioration judged due to ICH hematoma expansion meeting volume criteria may be randomized if surgery can commence within 8 hours of clinical deterioration
- Moderate neurological deficit (NIHSS≥6)
- Pre-stroke mRS ≤3 (independent function or requiring only minor domestic assistance and able to manage alone for at least 1 week).
- CTA or MRA is performed and does not show an underlying vascular lesion
Exclusion Criteria:
- Brainstem ICH
- ICH secondary to trauma, where brain injury is judged more likely to be due to the broad effects of trauma rather than the focal ICH.
- Hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency (in liver disease, INR>1.4).
- Platelet count <75,000
- Unreversible heparinization or anticoagulation. If reversing warfarin, INR should be ≤1.4 before procedure commences. Reversal of heparin by protamine, dabigatran by idarucizumab and rivaroxaban, apixaban and enoxaparin by andexanet (where available) is permitted. Unreversed anticoagulation with a last dose within 48 hours is an exclusion.
- Recent (<12 hours) parenteral GPIIb/IIIa antagonist.
- Recent (<1 hour) thrombolysis. If the ICH has occurred between 1 and 12 hours following thrombolysis, cryoprecipitate (1U per 10kg) and tranexamic acid must be administered prior to treatment.
- Participation in any investigational study in the last 30 days
- Pregnant women (clinically evident)
- Co-morbidities or advance care directive preventing general anaesthesia for the procedure.
- Known terminal illness such that the patients would not be expected to survive a year.
- Planned withdrawal of care or comfort care measures.
- Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04434807
Contact: Melbourne Brain Centre at the Royal Melbourne Hospital | +61 3 9342 4424 | info@thembc.org.au |
Australia, New South Wales | |
John Hunter Hospital | Recruiting |
Newcastle, New South Wales, Australia, 2305 | |
Contact: Michelle Russell, RN +61 2 4921 3481 michelle.russell@health.nsw.gov.au | |
Principal Investigator: Carlos Garcia-Esperon | |
Prince of Wales Hospital | Not yet recruiting |
Sydney, New South Wales, Australia, 2031 | |
Contact: Fanfan Tian +61 2 9382 8891 huiqiao.tian@unsw.edu.au | |
Principal Investigator: Ken Butcher | |
Royal Prince Alfred Hospital | Not yet recruiting |
Sydney, New South Wales, Australia, 2050 | |
Contact: Kylie Tastula +61 2 9515 4596 Kylie.Tastula@health.nsw.gov.au | |
Principal Investigator: John Worthington | |
Westmead Hospital | Not yet recruiting |
Sydney, New South Wales, Australia, 2145 | |
Principal Investigator: Mark Dexter | |
Liverpool Hospital | Recruiting |
Sydney, New South Wales, Australia, 2170 | |
Contact: Lisa Tran +61 2 8738 7170 Lisa.Tran@health.nsw.gov.au | |
Principal Investigator: Dennis Cordato | |
Australia, Queensland | |
The Royal Brisbane and Women's Hospital | Recruiting |
Brisbane, Queensland, Australia, 4029 | |
Contact: Liam Maclachlan +61 7 3365 1111 liam.maclachlan@health.qld.gov.au | |
Principal Investigator: Hamish Alexander | |
Princess Alexandra Hospital | Not yet recruiting |
Brisbane, Queensland, Australia, 4102 | |
Principal Investigator: Jeff Webster | |
Gold Coast University Hospital | Recruiting |
Southport, Queensland, Australia, 4215 | |
Contact: Victoria Cottam +61 7 5687 6395 Victoria.Cottam@health.qld.gov.au | |
Principal Investigator: Peter Bailey | |
Australia, South Australia | |
The Royal Adelaide Hospital | Recruiting |
Adelaide, South Australia, Australia, 5000 | |
Contact: Jennifer Cranefield, RN +61 8 7074 2900 jennifer.cranefield@sa.gov.au | |
Principal Investigator: Timothy Kleinig | |
Australia, Victoria | |
The Alfred Hospital | Recruiting |
Melbourne, Victoria, Australia, 3004 | |
Contact: Andrea Moore, RN +61 3 9903 8655 andrea.moore@alfred.org.au | |
Principal Investigator: Geoffrey Cloud | |
The Austin Hospital | Not yet recruiting |
Melbourne, Victoria, Australia, 3084 | |
Contact: Dennis Young, RN +61 3 9496 4953 dennis.young@austin.org.au | |
Principal Investigator: Vincent Thijs | |
Monash Medical Centre | Not yet recruiting |
Melbourne, Victoria, Australia, 3168 | |
Contact: May Chong, RN +61 3 9594 3836 Mee.Chong@monashhealth.org | |
Principal Investigator: Henry Ma | |
The Royal Melbourne Hospital | Recruiting |
Parkville, Victoria, Australia, 3050 | |
Contact: Amy McDonald, RN +61 3 9342 4424 amy.mcdonald@mh.org.au | |
Principal Investigator: Bruce Campbell |
Principal Investigator: | Timothy Kleinig | Royal Adelaide Hospital/University of Adelaide | |
Principal Investigator: | Amal Abou-Hamden | Royal Adelaide Hospital/University of Adelaide | |
Principal Investigator: | John Laidlaw | Royal Melbourne Hospital/University of Melbourne | |
Principal Investigator: | J Mocco | Icahn School of Medicine, Mt Sinai Hospital, New York | |
Principal Investigator: | Christopher Kellner | Icahn School of Medicine, Mt Sinai Hospital, New York | |
Principal Investigator: | Stephen Davis | Royal Melbourne Hospital/University of Melbourne | |
Principal Investigator: | Bruce Campbell | Royal Melbourne Hospital/University of Melbourne |
Responsible Party: | Bruce Campbell, Professorial Fellow, Department of Medicine, Royal Melbourne Hospital, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne |
ClinicalTrials.gov Identifier: | NCT04434807 |
Other Study ID Numbers: |
MBC2001 |
First Posted: | June 17, 2020 Key Record Dates |
Last Update Posted: | October 25, 2021 |
Last Verified: | October 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Anonymized individual patient data will be uploaded to the Virtual Stroke Trials Archive (http://www.virtualtrialsarchives.org/vista/) 2 years after the publication of the primary manuscript. Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA-ICH steering committee. |
Time Frame: | 2 years after the publication of the primary manuscript |
Access Criteria: | Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA-ICH steering committee. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
neurosurgery minimally invasive |
Cerebral Hemorrhage Hemorrhage Pathologic Processes Intracranial Hemorrhages Cerebrovascular Disorders |
Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases |